Barclays
VYNE icon

Barclays’s VYNE Therapeutics VYNE Stock Holding History

Barclays’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$188 – 5504
2024
Q3 		$188 Buy
+100
New +$190 ﹤0.01% 5167
2020
Q3 		– Sell
-1,748
Closed -$219K – 5614
2020
Q2 		$219K Buy
1,748
+1,446
+479% +$196K ﹤0.01% 3996
2020
Q1 		$59K Buy
302
+83
+38% +$26K ﹤0.01% 5124
2019
Q4 		$73K Buy
219
+109
+99% +$36.3K ﹤0.01% 5621
2019
Q3 		$35K Sell
110
-34
-24% -$11K ﹤0.01% 6062
2019
Q2 		$62K Buy
144
+98
+213% +$48.5K ﹤0.01% 5993
2019
Q1 		$27K Buy
46
+42
+1,050% +$20.2K ﹤0.01% 6236
2018
Q4 		$1K Sell
4
-49
-92% -$21.9K ﹤0.01% 6843
2018
Q3 		$37K Buy
53
+44
+489% +$27.2K ﹤0.01% 6236
2018
Q2 		$5K Sell
9
-9
-50% -$7K ﹤0.01% 6710
2018
Q1 		$50K Buy
+18
New +$43.8K ﹤0.01% 5909

Other funds holding VYNE

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's VYNE Position: Q4 2024 in Review

Barclays sold out of VYNE Therapeutics (VYNE) in Q4 2024, closing a stake of 100 shares — an estimated $188 sold.

Barclays first reported a position in VYNE in Q1 2018 and held it in 11 quarters. The position peaked at $219K in Q2 2020. 35 funds tracked by Wall St. Rank hold VYNE as of Q4 2024.

  • Barclays reported no remaining VYNE Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Barclays sold 100 VYNE Therapeutics shares in Q4 2024, an estimated $188.
  • Barclays first reported a position in VYNE Therapeutics in Q1 2018 and held it in 11 quarters.
  • Barclays's VYNE Therapeutics position peaked at $219K in Q2 2020.
  • 35 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.